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 The vertebrate neural retina is comprised of seven major
cell types organized into defined layers, all of which are de-
rived from the eye field, a subpopulation of cells in the ante-
rior neural plate [1,2]. The eye field is defined by the overlap-
ping expression of several transcription factors that are thought
to functionally define those cells that give rise to the neural
retina, sometimes referred to as the most primitive retinal stem
cells [3-6]. The earliest expressed eye field transcription fac-
tors, rx1 and pax6 are often termed “master” regulatory genes
of eye development because knock-out studies demonstrate
that each is necessary for eye formation, and over-expression
studies show that each is sufficient to produce ectopic eye tis-
sue [7-14]. Consistent with this idea, both genes continue to
be expressed throughout the regions that contain the retinal
stem and progenitor cells, i.e., the optic vesicle, the neural
layer of the optic cup and the ciliary marginal zone (CMZ) of
the differentiated retina. But in addition, both are expressed in
specific layers of the retina as the neurons differentiate, sug-
gesting that they may have later roles in defining different cell
types. Studies of rx1 are not as extensive as those ofpax6 al-
though the two genes share many similarities in function [15].
In Xenopus, rx1 is expressed in the outer nuclear layer (ONL;
rod and cone photoreceptors) and the outer zone of the inner
nuclear layer (OINL; horizontal, bipolar and Müller glial cells)
and pax6 is expressed in the ganglion cell layer (GCL; gan-
glion cells) and inner zone of the INL (IINL; amacrine cells)
[2,16,17].
It has been difficult to assess the later roles of rx1 and
pax6 because both are required for establishing the eye field.
Recently, a conditional knock-out of pax6 in the mouse CMZ
demonstrated that pax6 is necessary for continued production
of all retinal cell types except amacrine cells [18], but there
has been no similar report to date for rx1 function. We are
particularly interested in identifying whether rx1 or pax6 dif-
ferentially impact amacrine cell fate because previous work
showed that Xenopus retinal precursors have different devel-
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86opmental potentials to produce subtypes of amacrine cells [6].
Early embryonic blastomere precursors are differentially bi-
ased towards producing dopamine (DA), neuropeptide Y
(NPY) and serotonin (5HT) amacrine cells [19,20], whereas
there is no bias to produce GABA or glycine amacrine cells
[21]. Labeling of single cells in the eye field demonstrated
that about half of these cells are multipotent, producing cell
types in all layers, and about half are biased towards INL fates,
in particular amacrine cells [22]. Sampling of all quadrants of
the eye field and both deep and superficial ectodermal layers
produced both types of progenitors (multipotent and biased),
indicating that they are intermixed throughout the eye field.
Furthermore, both DA and NPY amacrine cells, but not 5HT
amacrine cells, appear to be lineage restricted during eye field
stages [22].
These observations suggest that genes expressed in the
eye field may differentially influence the specification of reti-
nal progenitors that give rise to different sets of differentiated
cell types. Amacrine cells are well known to be a diverse popu-
lation of interneurons; numerous different types have been de-
fined by neurotransmitter expression alone [23]. Because we
have quantified the number of several neurotransmitter sub-
types of amacrine cells that descend from defined embryonic
lineages [19-21], we tested whether altered Rx1 or Pax6 lev-
els or activity affects the production of three neurotransmitter
subtypes of amacrine cells. To avoid affecting the initial es-
tablishment of the eye field, we utilized hormone-inducible
mRNA constructs that could be activated after eye field for-
mation by synthetic hormone treatment [24,25], and we tar-
geted these constructs to a single embryonic blastomere lin-
eage whose specific contribution to each amacrine cell type
can be determined. We find that increased Rx1 levels in the
early eye field promotes NPY amacrine cells and represses
GABA and DA amacrine cells, and in the late eye field sig-
nificantly represses DA and NPY phenotypes but has a dimin-
ished effect on the GABA phenotype. Increased Pax6 levels
in the early eye field represses NPY and DA amacrine cells
but does not affect the GABA phenotype, and in the late eye
field significantly represses only the DA phenotype. These
results indicate that altered levels of Rx1 and Pax6 differen-
tially modify the ability of the eye field precursors to produce
different neurotransmitter subtypes of amacrine cells. Impor-
tantly, these effects varied for each of the subtypes investi-
gated, indicating that amacrine cells are not all specified by a
single genetic program. Furthermore, some cases were time-
dependent, indicating that the downstream effects change as
development proceeds.
METHODS
Generation and collection of embryos:  Fertilized Xenopus
laevis embryos were obtained from adult frogs induced to mate
after injection of human chorionic gonadotropin. After chemi-
cal removal of the jelly coat, embryos were selected as previ-
ously described [26] to allow the major blastomere precursor
of the retina (blastomere D1.1.1; Figure 1) to be identified
[27].
Targeted microinjection of synthetic mRNAs:  For gain-
of-function studies, the open reading frames of rx1 [10] and
pax6 [16] were fused by PCR to the ligand-binding domain of
the human glucocorticoid receptor (GR) as described [25]. For
loss-of-function studies, the same was done with previously
characterized rx1 Engrailed repressor (rx1EnR; [28]) and domi-
nant-negative pax6 (dnpax6) [11] constructs. Capped,
polyadenylated mRNAs were synthesized in vitro (Ambion,
Inc.), and mixed with green fluorescent protein (gfp; 100 pg)
mRNA as a lineage tracer. Each experimental mRNA (rx1-
GR, 50 pg; pax6-GR, 50 pg; rx1EnR-GR, 400 pg; dnpax6-GR,
60 pg) was microinjected into blastomere D1.1.1 (Figure 1).
The amount of test mRNA for injection was determined in
previous publications to: (1) effectively induce ectopic retinal
phenotypes with wild type constructs [10,11,13]; (2) effec-
tively reduce downstream target gene expression (engrailed
repressor construct) or endogenous protein activity (dominant-
negative construct) [11,28]; and (3) produce no signs of cell
toxicity [13]. Each experiment was repeated at least three times.
Exogenous gene expression was targeted to the D1.1.1
blastomere, which produces about 50% of the differentiated
cells in the tadpole retina [27], in order to avoid a global ef-
fect on the eye field that might perturb later retinogenesis.
Previous lineage studies showed that the descendants of the
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Figure 1. Blastomere injection and acti-
vation of gene expression.  A: The major
blastomere progenitor of the retina
(D1.1.1) in a 32-cell stage embryo was
injected with mRNAs encoding hor-
mone-inducible rx1or pax6 constructs
and gfp as a lineage tracer. B: Exogenous
gene expression was induced in early
(Stage 12) or late (Stage 16) eye fields
by incubation in dexamethasone solution.
Hormone treatment was continued
throughout the culture period. (C) Em-
bryos were raised to tadpole stages (stage
44/45) when amacrine cell subtypes have
differentiated and can be labeled with
neurotransmitter-specific antibodies.
87D1.1.1 blastomere are scattered throughout the eye field, in-
termixed with cells derived from adjacent blastomeres [27,29].
In addition, this blastomere produces a defined number of DA,
NPY and GABA amacrine cells [19,21], which allows one to
precisely quantify cell phenotype changes resulting from al-
terations in transcription factor level/activity.
After mRNA injection, the cells synthesize the fusion pro-
teins, but the GR domain forms a complex with endogenous
heat shock proteins that prevents the transcription factor from
entering the nucleus [24,25]. To uncouple this complex and
allow nuclear translocation, control and injected embryos were
incubated in synthetic hormone (10 mM dexamethasone) ac-
cording to published protocols [25]. To ensure that the GR
constructs function as expected, injected embryos were treated
with hormone immediately after mRNA injection; for each
construct these embryos phenocopied those injected with the
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Figure 2. Labeling of amacrine cell subtypes.  Sections of retina were labeled with antibodies to distinguish amacrine subtypes (red cells);
those descended from the injected blastomere express GFP (green cells). Top row: Large numbers of amacrine cells express GABA (left
panel). Large arrowheads indicate two GABA amacrine cells descended from D1.1.1 blastomere (green in middle panel and double-labeled in
merged right panel). Small arrow indicates a GABA amacrine cell that is not GFP-labeled. Middle row: Dopamine (DA) amacrine cells are
less abundant (left panel). Large arrowhead indicates a DA amacrine cell descended from D1.1.1 blastomere (green in middle panel and
double-labeled in merged right panel). Small arrows indicate two DA amacrine cells that are not GFP-labeled. Bottom row: NPY amacrine
cells also are less abundant (left panel). Large arrowhead indicates a NPY amacrine cell descended from D1.1.1 blastomere (green in middle
panel and double-labeled in merged right panel). Small arrows indicate two NPY amacrine cells that are not GFP-labeled. Each image was
collected with 40x oil lens, zoom set at 1.9, in a 1024x1024 pixel field, and pixel size equal to 0.12 µm.
88non-GR versions, i.e., wild-type mRNAs [10,11,16,28]. For
the experiments reported herein, embryos were treated with
hormone starting at two different time points in eye field de-
velopment (stage 12, early neural plate; stage 16, neural fold)
[30]; hormone treatment was maintained in the medium
throughout the culture period (Figure 1). Experiments in tis-
sue culture and in whole embryos with similar GR-fusion con-
structs indicate that robust protein activation occurs rapidly
(within 90 min) after hormone treatment, and is maintained
for several days [24,25,31,32]. Therefore, we assume that the
GR-fusion proteins are available to affect downstream targets
throughout the culture period of our experiments. Some em-
bryos were injected with the GR-constructs and raised in the
absence of hormone; DA amacrine cell numbers were un-
changed from controls indicating that the GR-constructs have
no effects in the absence of hormone, in accord with published
accounts [24,25,31,32]. Control embryos were injected with
only gfp mRNA and treated with dexamethasone at eye field
stages; amacrine subtype cell counts from these embryos were
identical to those from gfp mRNA-injected embryos not ex-
posed to hormone [19,21], indicating that hormone treatment
alone does not affect amacrine cell fates.
Immunostaining and cell counting:  Embryos were raised
in the continuous presence of hormone to stage 44/45, fixed
in 4% paraformaldehyde solution (MEMPFA;[33]) and
scanned for GFP expression to analyze only embryos in which
exogenous gene expression was successful. Embryos were
cryoprotected overnight at 4 °C in 30% sucrose/0.1 M phos-
phate buffer solution, embedded in Tissue-Tek OCT medium
(Miles, Inc.), and cut serially (14 mm) with a cryostat.
Immunostaining was carried out as previously described [19]
using mouse anti-tyrosine hydroxylase (1:200; Immunostar)
to detect DA amacrine cells, rabbit anti-GABA (1:500;
Immunostar) to detect GABA amacrine cells and rabbit anti-
NPY (1:200; Immunostar) to detect NPY amacrine cells.
AlexaFluor-conjugated Texas Red goat anti-mouse IgG or goat
anti-rabbit IgG secondary antibodies (Molecular Probes) were
applied at a concentration of 1:200. Sections were analyzed
using an epifluorescence microscope equipped with a dual pass
GFP/Texas Red barrier filter set. The total number of
immunolabeled cells and the number of these cells that also
were GFP labeled was counted in every section through the
retina (about 35-40 sections per retina); positive cells were
confirmed by focusing through the entire thickness of the sec-
tion with single pass Texas Red and single pass GFP barrier
filters. Fluorescent images were collected with a BioRad
MRC1024 laser scanning confocal microscope.
The proportion of immuno-positive cells that were also
labeled with GFP (i.e., derived from the mRNA-injected lin-
eage) was calculated. Percent contributions of the D1.1.1 lin-
eage to a particular amacrine subtype after stage 12 induction
or stage16 induction were independently compared to those
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Figure 3. Altered Rx1 levels/activity affect all
three amacrine cell subtypes.  rx1 gain-of-
function (dark blue bars) and loss-of function
(rx1-EnR; light blue bars) were induced at
early (St. 12) or late (St. 16) eye field stages.
The percent contribution that the injected blas-
tomere lineage made to the total number of
the subtype was determined for: (A) GABA,
(B) DA and (C) NPY amacrine cells. Bars in-
dicate SEM. A single asterisk (*) indicates a
significant difference (p<0.05) compared to
gfp mRNA-injected control embryos that also
were treated with dexamethasone (green bars).
A double asterisk (**) over a stage 16 bar in-
dicates a significant difference (p<0.05) com-
pared to stage 12 induction data. All samples
passed the equal variance test. rx1 gain-of-
function at both eye field stages caused a sig-
nificant reduction of GABA and DA amacrine
cells, but the GABA reduction was signifi-
cantly less at stage 16. In contrast, NPY ama-
crine cells were reduced only at the late stage.
rx1 loss-of-function increased GABA cell pro-
duction and reduced DA amacrine cell pro-
duction equivalently at both eye field stages;
it significantly decreased NPY amacrine cells
only at stage 12.
89from gfp mRNA-injected control embryos that were similarly
treated with dexamethasone (n=10 embryos per data set) by
the Student’s unpaired t-test (<0.05); each treatment data set
passed the equal variance test. The Student’s unpaired t-test
also was used to determine if there is a significant difference
between the stage 12 and stage 16 induction data sets for each
neurotransmitter/injected mRNA group.
RESULTS
Altering Rx1 level/activity at eye field stages differentially af-
fects amacrine subtypes:  It has been well-established that rx1
is both necessary and sufficient to establish the eye field and
it is proposed to maintain the retinal stem cells of the optic
cup, vesicle and CMZ. Its later expression in the ONL and
OINL of the layered retina suggests that it may additionally
repress the production of amacrine cells, which reside in the
IINL. We tested whether increasing the level of Rx1 in the
eye field, when biased INL progenitors have been identified
[22], affects the production of three neurotransmitter subtypes
of amacrine cells. In gfp mRNA-injected, hormone-treated
control embryos the D1.1.1 lineage produces about 16% of
GABA amacrine cells (Figure 2, Figure 3A). Increasing Rx1
levels in this lineage by injection of rx1-GR mRNA and sub-
sequent hormone treatment beginning at stage 12 significantly
repressed this phenotype; this reduction was detectable but
significantly less dramatic after hormone treatment at stage
16 (Figure 3A), indicating a window of sensitivity to increased
levels of Rx1 during early eye field stages. Consistent with
these results that indicate that Rx1 negatively regulates the
production of GABA amacrine cells, decreasing Rx1 target
gene activation by injection of a repressive rx1 construct
(rx1EnR-GR mRNA) and subsequent hormone treatment be-
ginning at either eye field stage significantly increased GABA
amacrine cell numbers (Figure 3A). In gfp mRNA-injected,
hormone-treated control embryos the D1.1.1 lineage produces
about 60% of DA amacrine cells (Figure 2, Figure 3B). In-
creasing Rx1 levels beginning at either stage 12 or 16 signifi-
cantly repressed the D1.1.1 lineage contribution to DA ama-
crine cells (Figure 3B). Decreasing Rx1 target gene activation
beginning at either stage also reduced DA amacrine cell num-
bers (Figure 3B), but the effect was much smaller than that
resulting from Rx1 gain-of-function. In gfp mRNA-injected,
hormone-treated control embryos the D1.1.1 lineage produces
about 40% of the rare NPY amacrine cells (Figure 2, Figure
3C). Increasing Rx1 levels in this lineage beginning at stage
12 did not affect NPY amacrine cell numbers, whereas hor-
mone treatment at stage 16 caused a significant reduction.
Conversely, decreasing Rx1 target gene activation repressed
NPY amacrine cells when activated by hormone treatment
beginning at stage 12, but did not have a significant effect
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Figure 4. Altered Pax6 levels/activity differ-
entially affect amacrine cell subtypes.  pax6
gain-of-function (dark yellow bars) and loss-
of-function (dnpax6, light yellow bars) were
induced at early (St. 12) and late (St. 16) eye
field stages, and analyzed as in Figure 3. pax6
gain-of-function at either eye field stage sig-
nificantly reduced the D1.1.1 contribution to
DA amacrine cells, whereas it only affected
NPY cells at stage 12. pax6 loss-of-function
at both stages significantly increased GABA
cells and significantly decreased DA cells.
NPY amacrine cells were not significantly af-
fected by pax6 loss-of-function at either stage.
90when activated at stage 16. Thus, an early high level of Rx1 is
required for NPY amacrine cell production, whereas a later
high level of Rx1 represses it.
These data demonstrate that the levels of Rx1 and target
gene activation have differential effects on these three neu-
rotransmitter subtypes of amacrine cells, and that these ef-
fects are time-dependent. Increasing Rx1 levels beginning in
the early eye field allows NPY amacrine cells to form in nor-
mal numbers and represses GABA and DA amacrine cells,
whereas increasing Rx1 levels beginning in the late eye field
significantly represses DA and NPY phenotypes but has a di-
minished effect on the GABA phenotype.
Altering Pax6 level/activity at eye field stages alters a
different subset of amacrine subtypes:  pax6 also is both nec-
essary and sufficient to establish the eye field and is proposed
to specify the retinal stem/progenitor cells of the optic cup,
vesicle and CMZ. Although a conditional knock-out of pax6
indicates that this gene is not required for amacrine cell gen-
esis [18], its later expression in the IINL suggests that it may
promote the differentiation of some amacrine cell subtypes.
Increasing Pax6 levels in the D1.1.1 lineage by injection of
pax6-GR mRNA and subsequent hormone treatment begin-
ning at either eye field stage had no significant effect on GABA
amacrine cell numbers, whereas decreasing Pax6 activity by
injection of a dominant-negative construct (dnpax6-GR
mRNA) significantly increased GABA amacrine cells (Fig-
ure 4A). Increasing Pax6 levels beginning at either eye field
stage significantly decreased the numbers of DA amacrine cells
in the D1.1.1 lineage; decreasing Pax6 activity at either stage
also repressed DA amacrine cells but the effect was smaller
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Figure 5. The developmental programs that produce amacrine cell subtypes are differentially affected by Rx1 and Pax6 in a time-dependent
manner.  The effects on the number of amacrine cells produced after induction of the different Rx1 and Pax6 constructs at the two eye field
stages are summarized. Retinal stem cells (RSC) in the stage 12 eye field are repressed by Rx1 from producing GABA and DA amacrine cells,
but Rx1 is required for NPY amacrine cells. In contrast, Pax6 represses the production of DA and NPY amacrine cells. Loss-of-function of
either Rx1 (by Rx1EnR) or Pax6 (by dnPax6) is required for GABA amacrine cell production. In the stage 16 eye field, which is likely
comprised of both RSC and retinal progenitor cells (RPC) [22], Rx1 continues to repress DA amacrine cells, but the effect on GABA amacrine
cells is much reduced. In addition, Rx1 now represses NPY amacrine cells. Pax6 continues to repress DA cells, but the effect on NPY cells is
no longer detectable. As at stage 12, loss-of-function of either Rx1 (by Rx1EnR) or Pax6 (by dnPax6) is required for GABA amacrine cell
production. These data indicate that Rx1 and Pax6 differentially affect the production of the different amacrine subtypes over time. Because
both genes are considered to be transcriptional activators [28,43], their inhibitory effects on amacrine subtypes are likely to be transcription-
ally indirect.
91than that resulting from pax6 gain-of-function (Figure 4B).
This result is similar to the effects of Rx1 levels on DA ama-
crine cells (Figure 3B). Increasing Pax6 levels beginning at
stage 12 repressed NPY amacrine cell numbers, whereas hor-
mone treatment at stage 16 had no significant effect (Figure
4C). Decreasing Pax6 activity at either stage had no signifi-
cant effect on NPY amacrine cell numbers (Figure 4C). These
data indicate that: (1) increasing Pax6 levels beginning in the
early eye field represses NPY and DA amacrine cells but do
not affect the GABA phenotype; (2) increasing Pax6 levels
beginning in the late eye field significantly represses only the
DA phenotype; (3) decreasing Pax6 activity beginning at ei-
ther eye field stage increases GABA and represses DA ama-
crine cells; but (4) NPY cells are produced independent of
reduced Pax6 activity. Thus, although both Rx1 and Pax6 are
considered retinal stem cell gene products, their altered lev-
els/activity beginning during the period of development when
different INL progenitors have first been detected have differ-
ential impacts on the production of amacrine subtypes (Fig-
ure 5). Because both proteins are considered to be transcrip-
tional activators [28,34], their inhibitory effects on amacrine
subtypes are likely to be transcriptionally indirect.
DISCUSSION
 Much work in retinal development has focused on the ge-
netic mechanisms that specify cell types and their differentia-
tion at developmental stages after eye cup formation [35], but
little is known about how earlier events during eye develop-
ment affect these processes. Both rx1 and pax6 are expressed
during the initial formation of the eye field, and they are thought
to be crucial for the production of definitive retinal stem cells
because loss-of-function mutants result in severe eye defects
[7,8,10,12,14]. However, both genes continue to be expressed
differentially in particular layers of the differentiating retina,
suggesting that they may have additional, albeit differing, roles
in cell type specification. In addition, it has been demonstrated
that during eye field stages when these two genes are broadly
expressed in retinal stem cells, differentially biased progeni-
tors arise that produce predominantly INL cells including
amacrine cells [22]. Therefore, we sought to determine whether
altering Rx1 or Pax6 levels/activity during this period affects
amacrine subtype specification. We demonstrate that Rx1 or
Pax6 have differential effects on the production of three dif-
ferent neurotransmitter subtypes of amacrine cells (Figure 5).
Specification of amacrine cells:  A large number of tran-
scription factors affect the diversity and numbers of distinct
retinal cell types [34-40]. For example, a combination of bHLH
factors appears to be necessary for amacrine cell production.
Over-expression of NeuroD in rat retinal progenitor cells re-
sults in a nearly two-fold increase in amacrine cells [41], and
loss of NeuroD in combination with Ath3 knock-out reduces
amacrine cells [42]. Mouse triple knockouts for Ath3, Ngn2,
and Ash1 show a severe decrease in amacrine, horizontal and
bipolar cells, of which Ngn2 is the critical gene for the ama-
crine cells [43].
Much less is known about the role of homeobox-contain-
ing transcription factors in amacrine cell specification. Early
studies suggested that rx1 is not expressed in differentiated
retinal cells, but more recent work indicates that in human
and mouse, rx1 is expressed in several layers of the adult retina
[15]. In zebrafish, rx1 expression is detected in cone photore-
ceptors of the adult eye [44], and in Xenopus tadpole retina,
rx1 is expressed in the ONL and OINL [2,17]. Recent evi-
dence suggests that rx1 promotes photoreceptor cell fate (re-
viewed in [45]) and Rx/Rax interacts with the photoreceptor-
specific element, PCE-1, to activate its expression [46]. Em-
bryonic stem cells expressing rx1 produce cells having a pho-
toreceptor phenotype when cultured in the presence of em-
bryonic retinal cells [47].
Conditional inactivation of pax6 in mice in the distal op-
tic cup before the onset of differentiation results in the exclu-
sive production of amacrine cells, suggesting that late Pax6
activity is necessary for all cell types except amacrine cells
[18]. This study further showed that pax6 is required for the
expression of Ngn2, Ath5 and Ash1 but not for NeuroD, indi-
cating that the differentiation of amacrine cells is mediated by
NeuroD, in conjunction with Ath3 and perhaps other bHLH
factors, independently of Pax6.
Our results provide important new information regarding
amacrine cell specification by retinal transcription factors.
First, we are the first to report that altered Rx1 levels signifi-
cantly impact amacrine cell production. It is likely that we
were able to detect these changes because we manipulated
Rx1 levels after eye field formation and we monitored spe-
cific subtypes that can be identified with markers and pre-
cisely quantified due to their small numbers in the tadpole
retina. Second, the effects of altering Rx1 and Pax6 levels on
the three neurotransmitter subtypes were not the same, indi-
cating that different genetic programs may independently or
differentially affect amacrine subtype production. Third, Pax6
appears to differentially regulate amacrine subtypes. Our data
indicate that: (1) the DA amacrine phenotype is repressed by
both Rx1 and Pax6 throughout eye field stages; (2) Rx1
strongly represses the GABA phenotype whereas Pax6 does
not; (3) GABA amacrine cells can differentiate independent
of Pax6 and Rx1; and (4) NPY amacrine cells require Rx1 and
are repressed by Pax6 at early but not at late eye field stages
(Figure 5). A conditional pax6 knock-out in mouse [18] simi-
larly reported that pax6 is not required for GABA amacrine
cells, but is required for glycine amacrine cells. Thus, ama-
crine cells are not specified as a class by a single genetic pro-
gram; instead, progenitors of different amacrine cell subtypes
are differentially responsive to Rx1 and Pax6 at different de-
velopmental times (Figure 5). It should be mentioned that the
reduction of certain amacrine cell types is not due to cell death
or a change in fate to other tissues, but rather to effects on
proliferation and differential maintenance of stem and pro-
genitor marker genes [Zaghloul and Moody, unpublished].
Timing of the effects:  The timing of differentiation of the
different retinal cell types is well conserved in vertebrates.
Ganglion cells and horizontal cells are the first cells to be born
followed by cone photoreceptors, amacrine cells, rod photo-
receptors, bipolar cells, and finally Müller glia [4]. The tem-
poral order in which retinal cell types are born is consistently
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92maintained in vertebrates suggesting a role in cell type deter-
mination. In most animals, amacrine cells exit the terminal
cell cycle over a broad temporal window. For example, in
Xenopus, amacrine cells are born predominantly between stage
27 and 37 [48]. Our data indicate that the effects of altering
Rx1 and Pax6 levels/activity on amacrine cells depend upon
the time at which the changes are initiated (Figure 5); we as-
sume that these changes in protein levels/activity are main-
tained throughout retinogenesis after hormone treatment, based
on the long-lived activity of similar GR constructs in other
studies [24,25,31,32], but we do not have antibodies that rec-
ognize the fusion proteins to prove this point directly. With
this caveat in mind, although DA amacrine cell production
was equally affected by increased Rx1 or Pax6 levels begun
at either eye field stage, the NPY and GABA phenotypes
showed distinct temporal effects (Figure 5). GABA cells were
strongly repressed by Rx1 at the early stage and minimally
affected at the late stage. NPY cells were repressed by Rx1
only at the late stage, and were repressed by Pax6 only at the
early stage. Since a few studies in the rat retina suggest that
amacrine subtypes may have slightly different birthdates
[49,50], it is possible that altering Rx1 and Pax6, both of which
have been implicated in controlling proliferation [9,51], at
different eye field stages may differentially affect amacrine
subtype birthdates.
The different temporal effects we observed also may be
caused by the changing signaling environment in which cells
reside as the retina develops [37]. For example, retinal pro-
genitor cells that produce amacrine cells give rise to different
subsets of progeny depending upon the embryonic stage at
which the cells are isolated [52]. Temporal changes in NeuroD
activity, modulated by glycogen synthase kinase-3 activity,
also can affect cell fates [53]. Since Rx1 and Pax6 may hold
cells in an immature, multi-potent state [9,51], temporally al-
tering their levels of activity may regulate the competence of
the cells to respond to changing environmental cues and
thereby affect the production of different amacrine subtypes.
In addition, Rx1 and Pax6 likely interact in a time-depen-
dent manner with other eye field transcription factors, such as
Eye-gone [54], Six3 [55-59], Six6 [60-62] and Tll [63]. A re-
cent study shows that in Xenopus, as proposed in Drosophila
[64], there is a self-regulating feedback network of these fac-
tors that specifies the eye field to be the repository of retinal
stem cells [5]. These authors demonstrated that the expres-
sion of a cocktail of eye field factors (ET, Lhx2, Pax6, Rx1,
Six3, Six6, Tll) induced an ectopic eye field at high frequency.
They further demonstrate that ET functions upstream of Rx1,
which is upstream of Pax6, and that Tll and Six6 function
later in the network. Thus, eye field transcription factors regu-
late each other and themselves over developmental time to
provide the appropriate transcriptional environment for the
expression of a retinal fate. Altering Rx1 and Pax6 levels/ac-
tivity at different developmental times is likely to differen-
tially impact elements in this transcriptional network. Thus, it
will be important to study the effects of altering Rx1, Pax6
and the other eye field transcription factors in combination to
fully understand the roles of these proteins in amacrine cell
production.
The cross- and auto-regulatory interactions between the
transcription factors in the retinal transcriptional network may
explain two observations presented herein that at first glance
seem contradictory. First, the loss-of-function phenotypes for
both Rx1 and Pax6 are very similar for each of the three ama-
crine subtypes. This is not surprising if each gene regulates
the other in a feedback loop, as proposed elsewhere [5]. Sec-
ond, DA amacrine cells are significantly reduced by both in-
creased and decreased levels/activity of Rx1 and Pax6, albeit
the reduction is much less severe for the loss-of-function con-
dition. Perhaps the DA amacrine cell phenotype is quite sen-
sitive to the cross- and auto-regulatory part of the early tran-
scriptional network. Continued work on exactly how these
factors regulate each other will be critical for understanding
how they influence the determination of the many subtypes of
amacrine cells.
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